

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hepatic disease				
Liver fibrosis	IL-33 (NF-HEV)	<p>Patient and mouse studies suggest inhibiting IL-33 signaling could help treat liver fibrosis. In patients who have cirrhosis, serum samples had higher IL-33 than samples from healthy controls ($p < 0.001$). In mice, knocking out <i>Il-33</i> resulted in decreased chemical-, parasite- and biliary-induced hepatic fibrosis compared with no knockout. Next steps could include screening for and evaluating compounds that inhibit IL-33 signaling.</p> <p>SciBX 6(35); doi:10.1038/scibx.2013.963 Published online Sept. 12, 2013</p>	Patent and licensing information unavailable	<p>Mchedlidze, T. <i>et al. Immunity</i>; published online Aug. 15, 2013; doi:10.1016/j.immuni.2013.07.018 Contact: Stefan Wirtz, University of Erlangen-Nuremberg, Erlangen, Germany e-mail: stefan.wirtz@uk-erlangen.de</p>